OAKLAND, Calif. — The kitchen counter in the home of the Hayes family is scattered with the inhalers, sprays and bottles of pills that have allowed Hannah, 13, and her sister, Abby, 10, to excel at dance and gymnastics despite a horrific pollen season that has set off asthma attacks, leaving the girls struggling to breathe.
Asthma — the most common chronic disease that affects Americans of all ages, about 40 million people — can usually be well-controlled with drugs. But being able to afford prescription medications in the United States often requires top-notch insurance or plenty of disposable income, and time to hunt for deals and bargains.
The arsenal of medicines in the Hayeses’ kitchen helps explain why. Pulmicort, a steroid inhaler, generally retails for more than $175 in the United States, while pharmacists in Britain buy the identical product for about $20 and dispense it free to asthma patients. Albuterol, one of the oldest asthma medicines, typically costs $50 to $100 per inhaler in the United States, but it was less than $15 a decade ago, before it was repatented.
“The one that really blew my mind was the nasal spray,” said Robin Levi, Hannah and Abby’s mother, referring to her $80 co-payment for Rhinocort Aqua, a prescription drug that was selling for more than $250 a month in Oakland pharmacies last year but costs less than $7 in Europe, where it is available over the counter.
- Seattle man charged with vehicular homicide in cyclist’s death
- Paying the bill for U.S. Open at Chambers Bay
- Pursuit of big-money contract comes at a cost for Seahawks QB Russell Wilson
- ‘Historic’ tuition cut sets state apart from rest of U.S.
- Polygamous Montana trio applies for marriage license
Most Read Stories
The Centers for Disease Control and Prevention (CDC) puts the annual cost of asthma in the United States at more than $56 billion, including millions of potentially avoidable hospital visits and more than 3,300 deaths, many involving patients who skimped on medicines or did without.
“The thing is that asthma is so fixable,” said Dr. Elaine Davenport, who works in Oakland’s Breathmobile, a mobile asthma clinic whose patients often cannot afford prescription costs. “All people need is medicine and education.”
With its high prescription prices, the United States spends far more per capita on medicines than other developed countries. Drugs account for 10 percent of the country’s $2.7 trillion annual health bill, even though the average American takes fewer prescription medicines than people in France or Canada, said Gerard Anderson, who studies medical pricing at the Bloomberg School of Public Health at Johns Hopkins University.
Americans also use more generic medications than patients in any other developed country. The growth of generics has led to cheap pharmacy specials — less than $7 a month — for some treatments for high cholesterol and high blood pressure, as well as the popular sleeping pill Ambien.
But many generics are still expensive, even if insurers are paying the bulk of the bill. Generic Augmentin, one of the most common antibiotics, retails for $80 to $120 for a 10-day prescription ($400 for the brand-name version). Generic Concerta, a mainstay of treating attention-deficit disorder, retails for $75 to $150 per month, even with pharmacy-discount coupons. For some conditions, including asthma, there are few generics available.
While prescription-drug spending fell slightly last year, in part because of the recession, it is expected to rise as the economy recovers and as millions of Americans become insured under the Affordable Care Act, said Murray Aitken, executive director of IMS Health, a leading tracker of pharmaceutical trends.
Unlike other countries, where the government directly or indirectly sets an allowed national wholesale price for each drug, the United States leaves prices to market competition among pharmaceutical companies, including generic drugmakers. But competition is often a mirage in today’s health-care arena — a surprising number of lifesaving drugs are made by only one manufacturer — and businesses often successfully blunt market forces.
Asthma inhalers, for example, are protected by strings of patents — for pumps, delivery systems and production processes — that are hard to skirt to make generic alternatives, even when the medicines they contain are old, as they almost all are.
The repatenting of older drugs like some birth-control pills, insulin and colchicine, the primary treatment for gout, has rendered medicines that once cost pennies many times more expensive.
“The increases are stunning, and it’s very injurious to patients,” said Dr. Robert Morrow, a family practitioner in New York. “Colchicine is a drug you could find in Egyptian mummies.”
Pharmaceutical companies also buttress high prices by choosing to sell a medicine by prescription, rather than over the counter, so that insurers cover a price tag that would be unacceptable to consumers paying full freight. They even pay generic drugmakers not to produce cut-rate competitors in a controversial scheme called “pay for delay.”
Hannah and Abby Hayes were admitted to the hospital on separate occasions in 2005 with severe shortness of breath. Oakland, a city subject to pollution from its freeways and a busy seaport, has four times the hospital-admission rate for asthma as elsewhere in California.
The asthma rate nationwide among African Americans and people of mixed-racial backgrounds is about 20 percent higher than the average.
Robin Levi, a Stanford-trained lawyer who works for Students Rising Above, a group that helps low-income students attend college, is black. Her husband, John Hayes, an economist, is white. Their daughters have allergic asthma that is set off by animals, grass and weeds, but they also get wheezy when they have a cold.
While on medication, neither Hayes girl has been in the hospital since her initial diagnosis. Their mother tweaks dosing, adding extra medicine if they have a cold or plan to ride horses.
Pricing to demand
For most patients, asthma medicines are life-changing. In economic terms, that means demand for the medicines is inelastic. Unlike a treatment for acne that a patient might drop if the price became too high, asthma patients will go to great lengths to obtain their drugs.
For pharmaceutical companies, that has made these respiratory medicines blockbusters: the two best-selling combination inhalers, Advair and Symbicort, had global sales of $8 billion and $3 billion last year. Each inhaler, typically lasting a month, retails for $250 to $350 in the United States.
Asked to explain the high price of inhalers, the two major manufacturers say the calculus is complicated.
“Our pricing is competitive with other asthma treatments currently on the market,” Michele Meixell, the U.S. spokeswoman for AstraZeneca, which makes Symbicort and other asthma drugs, wrote in an email. She added that low-income patients without insurance could apply for free drugs from the company.
Juan Carlos Molina, the director of external communication for GlaxoSmithKline, which makes Advair, said in an email that the price of medicines was “closely linked to this country’s model for delivery of care,” which assumes that health insurance will pick up a significant part of the cost. An average co-payment for Advair for commercially insured patients is $30 to $45 a month, he added.
Even with good insurance, the Hayeses expect to spend nearly $1,000 this year on their daughters’ asthma medicines; their insurer spent much more than that. The total would have been more than $4,000 if the insurer had paid retail prices in Oakland, but the final tally is not clear because the insurer contracts with a prescription-benefits company that negotiates with drugmakers for undisclosed discounts.
Dr. Dana Goldman, director of the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California, said: “Producing these drugs is cheap. And yet we are paying very high prices.” He added that because inhalers were so effective at keeping patients out of hospitals, most national-health systems made sure they were free or inexpensive.
But in the United States, even people with insurance coverage struggle.
Lisa Solod, 57, a freelance writer in Georgia, uses her inhaler once a day, instead of twice, as usually prescribed, because her insurance does not cover her asthma medicines.
John Aravosis, 49, a political blogger in Washington, buys a few Advair inhalers at $45 each during vacations in Paris, because his insurance caps prescription coverage at $1,500 a year.
Sharon Bondroff, 68, an antiques dealer in Maine on Medicare, scrounges samples of Advair from doctors. Bondroff remembers a time, not so long ago, when inhalers “were really cheap.”
The sticker shock for asthma patients began several years back, when the federal government said it would require manufacturers of spray products to remove chlorofluorocarbon propellants because they harmed the environment. That meant new inhaler designs. And new patents. And skyrocketing prices.
As drugs age and lose patent protection, the costs of treatment can fall significantly because of generic competition, particularly if a pill has only one active ingredient and is simple to replicate.
When Singulair, a pill the Hayes girls take daily to block allergic reactions in the lungs, lost its patent protection last year, generics rapidly entered the market. The price of the drug has dropped from $180 a month to as low as $15 to $20 with pharmacy coupons.
But sprays, creams, patches, gels and combination medicines are more difficult to copy exactly to make a generic that meets Food and Drug Administration (FDA) standards.
No generic inhalers
A result is that there are no generic asthma inhalers available in the United States. But they are available in Europe, where health regulators have been more flexible about mixing drugs and devices and where courts have been quicker to overturn drug-patent protection.
The FDA acknowledges that the lack of inhaled-generic medicines and topical creams has been costly for patients, but it attributes that to “difficult, longstanding scientific challenges,” because measuring drug activity deep into the lung is complicated, said Sandy Walsh, a spokeswoman for the agency.
Dr. Robert Lionberger, the agency’s acting deputy director in the office of generic drugs, said that research into the development of generic-inhaled medicines was the agency’s highest priority but that the effort had been stalled because of budget cuts imposed by Congress.
Even so, experts say, a significant problem is that none of the agencies that determine whether medicines come to market in the United States are required to consider patient access, affordability or need.
“Drug patents are easy to get, and the patent office is deluged,” said Dr. Aaron Kesselheim, a pharmaceutical-policy expert at Harvard Medical School. “The FDA approves based on safety and efficacy. It doesn’t see its role as policing this process.”
For asthma patients in the United States, the best the market has yielded are a few faux generics that are often only marginally cheaper than the brand-name versions.
Threat to profits
There are good reasons drug companies are feeling threatened. In the past several years, some best-selling medicines, such as Lipitor for high cholesterol and Plavix for blood thinning, have been largely replaced by cheap generics in a very competitive market.
In 2012, that led to $29 billion in savings for patients, said Aitken of IMS Health, or $29 billion in lost revenues for drugmakers. Eighty-four percent of prescriptions dispensed last year were for generic medications.
Although drug companies generally remain highly profitable, recent trends have meant tough times for some companies, including Merck, whose profits crashed 50 percent this year primarily because the patent expired on its best-selling asthma pill, Singulair.
Drug prices in the United States are set in hundreds of negotiations by hospitals, insurers and pharmacies with drug manufacturers, with deals often brokered by powerful middlemen called group-purchasing organizations and pharmacy-benefit managers, who leverage their huge size to demand discounts.
The process can get nasty; if mediators offer too little for a given product, manufacturers may decide not to produce it or permanently drop out of the market, reducing competition.
With such jockeying determining supply, products can simply disappear and prices for vital medicines can fluctuate far more than they do for a carton of milk.
After the price of Abby Hayes’ Rhinocort Aqua nasal spray rose abruptly, it was unavailable for many months. That sent her family scrambling to find other prescription sprays, each with a price tag of more than $150.
This year the price of Advair dropped 10 percent in France, but in pharmacies in the Bronx, it has doubled in the past two years.
“Price always goes up”
In Georgia, Solod, the freelance writer, found the same thing.
“Every time I get Advair, the price is different,” she said. “And the price always goes up. It never comes down.”
Twenty years ago, drugs that could safely be sold directly to patients typically moved off the prescription model as their patent life ended. That brought valuable medicines like nondrowsy antihistamines and acid reducers to drugstore shelves.
But with profitable prescription products now selling for $100 per tiny bottle, there is little incentive to make the switch, because over-the-counter drugs rarely succeed if they cost more than $20.
As a result, a number of products that are sold directly to patients in other countries remain available only by prescription in the United States. That includes a version of the popular but expensive steroid-nasal spray used by Abby Hayes, which is available over the counter in London for under $15 at the Boots pharmacy chain.
During this high pollen season, Abby had to cut short a gymnastics practice, and her sister, Hannah, missed one day of school because of breathing problems, the first time in many years.
But with parents who can afford to get the medicine they require, both are now doing fine.